TR200000145T2 - Kemik erimesini durdurmak için bir yöntem - Google Patents

Kemik erimesini durdurmak için bir yöntem

Info

Publication number
TR200000145T2
TR200000145T2 TR2000/00145T TR200000145T TR200000145T2 TR 200000145 T2 TR200000145 T2 TR 200000145T2 TR 2000/00145 T TR2000/00145 T TR 2000/00145T TR 200000145 T TR200000145 T TR 200000145T TR 200000145 T2 TR200000145 T2 TR 200000145T2
Authority
TR
Turkey
Prior art keywords
bone resorption
clodronate
methods
stop bone
stop
Prior art date
Application number
TR2000/00145T
Other languages
English (en)
Turkish (tr)
Inventor
G. Daifotis Anastasia
C. Santora Ii Arthur
John Yates A.
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000145(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of TR200000145T2 publication Critical patent/TR200000145T2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
TR2000/00145T 1997-07-22 1998-07-17 Kemik erimesini durdurmak için bir yöntem TR200000145T2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Publications (1)

Publication Number Publication Date
TR200000145T2 true TR200000145T2 (tr) 2000-05-22

Family

ID=27451690

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00145T TR200000145T2 (tr) 1997-07-22 1998-07-17 Kemik erimesini durdurmak için bir yöntem

Country Status (31)

Country Link
EP (5) EP0998292B1 (enExample)
JP (2) JP3479780B2 (enExample)
KR (3) KR20030097611A (enExample)
CN (3) CN1602879A (enExample)
AT (2) ATE357921T1 (enExample)
AU (1) AU8493698A (enExample)
BG (1) BG66282B1 (enExample)
BR (1) BR9810779A (enExample)
CA (1) CA2294595C (enExample)
CY (2) CY1107535T1 (enExample)
DE (6) DE122006000009I1 (enExample)
DK (2) DK1175904T3 (enExample)
EA (1) EA004544B2 (enExample)
EE (1) EE05603B1 (enExample)
ES (3) ES2253136T1 (enExample)
HK (4) HK1042230A1 (enExample)
ID (1) ID24096A (enExample)
IL (1) IL133535A0 (enExample)
IS (3) IS5315A (enExample)
LU (2) LU91222I2 (enExample)
NL (2) NL300223I1 (enExample)
NO (1) NO20000323L (enExample)
NZ (1) NZ501807A (enExample)
PL (1) PL195272B1 (enExample)
PT (2) PT1175904E (enExample)
SG (2) SG139556A1 (enExample)
SI (1) SI0998292T1 (enExample)
SK (1) SK932000A3 (enExample)
TR (1) TR200000145T2 (enExample)
UY (1) UY25950A1 (enExample)
WO (1) WO1999004773A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69916326T2 (de) * 1998-12-25 2005-03-17 Yamanouchi Pharmaceutical Co., Ltd. Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom
NZ515541A (en) * 1999-05-21 2003-03-28 Novartis Ag Pharmaceutical compositions comprising bisphosphonates to treat angiogenesis
CN100349574C (zh) * 1999-07-19 2007-11-21 东丽株式会社 牙周疾病用剂
WO2001046040A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Blister package for pharmaceutical treatment card
IL142515A0 (en) * 1999-12-20 2002-03-10 Merck & Co Inc Pharmaceutical kit
MXPA02009924A (es) * 2000-04-07 2004-08-19 Univ Texas Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida.
DE60113537T3 (de) 2000-06-20 2013-05-29 Novartis Ag Methode zur verabreichung von biphosphonaten
RU2288722C2 (ru) * 2000-06-20 2006-12-10 Новартис Аг Способ введения бисфосфонатов
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
JP2004528365A (ja) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト 骨再吸収症および骨粗しょう症の処置または予防におけるビスホスホネートの吸入投与方法
DE60317061T2 (de) * 2002-05-10 2008-07-24 F. Hoffmann-La Roche Ag Ibandronsäure zur behandlung und vorbeugung von osteoporose
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
NZ545804A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
EP1937362B1 (en) * 2005-09-16 2013-03-27 Selamine Ltd. Bisphosphonate formulation
KR20170104664A (ko) * 2010-12-06 2017-09-15 에프락스 파머슈티컬즈 소시에떼 아노님 신속한 용해 특성을 구비한 안정한 발포성 비스포스포네이트 제형
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
ES2074769T3 (es) * 1991-07-01 1995-09-16 Gergely Gerhard Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo.
CA2122479C (en) * 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
DK0648120T3 (da) * 1992-06-30 1998-01-19 Procter & Gamble Pharma Anvendelse af phosphonater til behandling af osteoporose
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
JPH11506750A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 慢性関節リウマチに係わる骨欠損に対するビスホスホネート療法
ATE256456T1 (de) * 1996-05-17 2004-01-15 Merck & Co Inc Biphosphonat-formulierung mit brausewirkung

Also Published As

Publication number Publication date
CA2294595C (en) 2001-08-21
IS5315A (is) 1999-12-21
NO20000323L (no) 2000-03-20
EP1175904A2 (en) 2002-01-30
CY2007022I2 (el) 2012-01-25
KR20010022110A (ko) 2001-03-15
ATE357921T1 (de) 2007-04-15
UY25950A1 (es) 2000-09-29
JP2005068010A (ja) 2005-03-17
EP1175903A2 (en) 2002-01-30
CY1107535T1 (el) 2012-01-25
EA004544B2 (ru) 2006-12-29
CN1265035A (zh) 2000-08-30
KR20030097610A (ko) 2003-12-31
BR9810779A (pt) 2000-07-25
KR20030097611A (ko) 2003-12-31
DE01201911T1 (de) 2007-10-18
DE69803291T2 (de) 2002-08-08
LU91222I2 (fr) 2006-04-18
CY2007022I1 (el) 2012-01-25
WO1999004773A2 (en) 1999-02-04
NL300292I1 (nl) 2007-11-01
EA200000151A1 (ru) 2000-10-30
PL338635A1 (en) 2000-11-06
EP1132088A3 (en) 2002-04-24
CN1166365C (zh) 2004-09-15
SI0998292T1 (en) 2002-04-30
HK1040494A1 (en) 2002-06-14
LU91364I2 (fr) 2007-11-12
WO1999004773A9 (en) 1999-10-28
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
BG66282B1 (bg) 2013-01-31
CN1299689C (zh) 2007-02-14
HK1040495A1 (en) 2002-06-14
EE200000040A (et) 2000-10-16
DE01201913T1 (de) 2007-02-08
DE122006000009I1 (de) 2006-06-14
BG104093A (en) 2000-10-31
EP1151752A3 (en) 2002-12-18
EP1175904B1 (en) 2007-03-28
EP1132088A2 (en) 2001-09-12
HK1024166A1 (en) 2000-10-05
EE05603B1 (et) 2012-12-17
DE69803291D1 (de) 2002-02-21
SG109478A1 (en) 2005-03-30
ES2269014T3 (es) 2007-05-01
DK1175904T3 (da) 2007-05-07
PT998292E (pt) 2002-04-29
KR100391732B1 (ko) 2003-07-16
CA2294595A1 (en) 1999-02-04
CN1602880A (zh) 2005-04-06
HK1042232A1 (en) 2002-08-09
EP0998292A2 (en) 2000-05-10
EA004544B1 (ru) 2004-06-24
CN1602879A (zh) 2005-04-06
ES2269014T1 (es) 2007-04-01
NL300223I1 (nl) 2006-04-03
IS7231A (is) 2004-04-21
EP1175904B8 (en) 2007-05-09
IL133535A0 (en) 2001-04-30
EP1151752A2 (en) 2001-11-07
EP1175904A3 (en) 2002-12-18
NZ501807A (en) 2003-02-28
DE69837450D1 (de) 2007-05-10
EP1175903A3 (en) 2002-12-18
JP3479780B2 (ja) 2003-12-15
IS7230A (is) 2004-04-21
AU8493698A (en) 1999-02-16
PL195272B1 (pl) 2007-08-31
ES2253136T1 (es) 2006-06-01
HK1042230A1 (en) 2002-08-09
EP0998292B1 (en) 2001-11-21
ES2164447T3 (es) 2002-02-16
PT1175904E (pt) 2007-04-30
JP2002502433A (ja) 2002-01-22
ID24096A (id) 2000-07-06
DE69837450T2 (de) 2007-08-23
WO1999004773A3 (en) 1999-04-15
SK932000A3 (en) 2000-09-12
ATE209037T1 (de) 2001-12-15
DK0998292T3 (da) 2002-05-13
DE122007000063I1 (de) 2007-12-20

Similar Documents

Publication Publication Date Title
TR200000145T2 (tr) Kemik erimesini durdurmak için bir yöntem
NZ527157A (en) Compositions for delivering bisphosphonates
NZ272608A (en) Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
NZ545804A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
EP1178810B8 (en) Use of bisphosphonic acids for treating angiogenesis
BR0309691A (pt) Formulação de ibandronato em alta dose
TR200805763T2 (tr) Kemik erimesini durdurmak için bir yöntem
BR9609477A (pt) Composto composição farmacêutica e processos para preparação de tiludronato dissódico e para obtenção de uma composição farmacêutica
MX9709906A (es) Uso de bisfosfonatos para preparar composiciones para prevenir perdida de hueso asociada con terapia inmunosupresora.